Drugs Containing Excipient (Inactive Ingredient) LACTOSE, ANHYDROUS

Branded drugs containing LACTOSE, ANHYDROUS excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT Rx USA LLC	EXALGO	hydromorphone hydrochloride	16590-942	LACTOSE, ANHYDROUS

Generic drugs containing LACTOSE, ANHYDROUS excipient

Company	Ingredient	NDC	Excipient
STAT Rx USA LLC	hydromorphone hydrochloride	16590-942	LACTOSE, ANHYDROUS
STAT Rx USA LLC	losartan potassium	16590-952	LACTOSE, ANHYDROUS
Rebel Distributors Corp	erythromycin ethylsuccinate and sulfisoxazole acetyl	21695-690	LACTOSE, ANHYDROUS
HJ Harkins Company Inc	ondansetron hydrochloride	52959-991	LACTOSE, ANHYDROUS
Physicians Total Care Inc	erythromycin ethylsuccinate and sulfisoxazole acetyl	54868-0971	LACTOSE, ANHYDROUS

Lactose, Anhydrous Pharmaceutical Excipient: Market Dynamics, Financial Trajectory, Suppliers, and Regulatory Outlook

Last updated: August 7, 2026

Anhydrous lactose is a mature pharmaceutical excipient with stable demand in direct-compression tablets, capsule filling, orally disintegrating tablets, and selected dry-powder inhalation applications. Its financial outlook is driven less by volume growth than by grade mix, qualification requirements, manufacturing capacity, energy costs, dairy-feedstock economics, and customer migration toward high-functionality excipients.

The market has limited compound-level patent protection. Commercial defensibility comes from particle engineering, crystallinity control, low-moisture manufacturing, microbial controls, regulatory documentation, supply reliability, and customer-specific formulation know-how. DFE Pharma, MEGGLE, Kerry, and regional lactose processors are the principal competitive reference points.

What is anhydrous lactose used for in pharmaceutical manufacturing?

Anhydrous lactose is lactose containing little or no crystallization water. It is used as a filler, diluent, carrier, and processing aid in solid oral dosage forms.

Application	Role of anhydrous lactose	Commercial relevance
Direct-compression tablets	Filler and compressibility modifier	Core growth segment
Hard capsules	Bulking agent and powder diluent	Stable demand
Orally disintegrating tablets	Diluent with selected grades	Niche but higher-value
Dry-powder inhalers	Carrier or co-carrier in selected formulations	Technical, qualification-intensive
Granulation	Diluent and blend component	Less differentiated than direct compression
Nutraceutical tablets	Filler and flow aid	Price-sensitive, lower regulatory value

Anhydrous lactose is selected when formulators need lower residual moisture than lactose monohydrate, improved compatibility with moisture-sensitive active pharmaceutical ingredients, or specific flow and compaction behavior. It is not interchangeable with all lactose grades. Particle-size distribution, morphology, bulk density, surface area, and hygroscopicity affect blend uniformity, tablet hardness, disintegration, and dissolution.

How does anhydrous lactose compare with lactose monohydrate?

Anhydrous lactose commands technical value when moisture control and direct compression performance are more important than the lowest material cost.

Attribute	Anhydrous lactose	Lactose monohydrate
Water content	Low	Higher due to crystallization water
Typical use	Direct compression and moisture-sensitive formulations	General tablet and capsule dilution
Processing value	Often higher in engineered grades	Broad and established
Cost position	Usually premium to commodity monohydrate	Generally lower
Supply base	More specialized	Broader
Formulation substitution	Requires development work	Often easier in conventional products
Inhalation relevance	Application-dependent	Common carrier form in many DPI systems

Dry-powder inhalers often use inhalation-grade lactose monohydrate or engineered lactose carrier particles. Anhydrous lactose should not be assumed to be the default inhalation grade. Inhalation use requires tighter control of particle-size fractions, surface properties, bioburden, and extractables or contaminants.

How large is the anhydrous lactose pharmaceutical market?

Public sources generally report lactose within broader pharmaceutical excipient or pharmaceutical-grade lactose markets rather than isolating anhydrous lactose as a separate category. Published market estimates therefore vary materially because they differ in geographic scope, inclusion of food and nutraceutical products, and treatment of inhalation-grade lactose.

The defensible commercial conclusion is that anhydrous lactose is a specialty subsegment of the larger pharmaceutical lactose market, with value growth likely exceeding volume growth. Its growth profile is linked to:

• Expansion of generic and branded solid oral dosage manufacturing.
• Growth in direct-compression tablet platforms.
• Increased use of low-moisture excipients for chemically sensitive APIs.
• Outsourcing to contract development and manufacturing organizations.
• Demand for inhalation and orally disintegrating dosage forms.
• Replacement of conventional lactose with engineered grades.
• Regulatory preference for documented, pharmacopeial, traceable supply chains.

Commodity lactose demand is exposed to price competition. Pharmaceutical anhydrous lactose has stronger pricing because customers qualify specific grades and suppliers, then face substantial switching costs.

What is driving the financial trajectory for anhydrous lactose?

The financial trajectory is a combination of moderate underlying volume growth and periodic price increases.

Feedstock and energy costs

Lactose is derived from dairy processing streams, particularly whey. Raw-material economics are therefore connected to milk production, cheese manufacturing, whey availability, transportation, drying energy, and utility costs. Spray drying and further particle engineering increase exposure to natural gas, electricity, maintenance, and environmental compliance expenses.

Grade mix

Revenue growth is strongest when customers adopt high-functionality grades rather than standard milled lactose. Premium products can include:

• Direct-compression grades.
• Narrow particle-size grades.
• Low-moisture grades.
• Inhalation-grade carriers.
• Granulated or agglomerated grades.
• Custom blends and customer-specific specifications.

Qualification economics

Pharmaceutical customers commonly require supplier audits, change-control commitments, certificates of analysis, stability data, elemental impurity assessments, residual solvent statements, allergen information, and documented supply continuity. A qualified supplier can retain business even when its material price is above food-grade alternatives.

Manufacturing concentration

The market has fewer qualified pharmaceutical suppliers than the broader lactose market. This concentration supports pricing during capacity constraints but increases customer concerns about dual sourcing, geopolitical exposure, and plant interruptions.

Product mix and inflation pass-through

Suppliers with a high proportion of pharmaceutical-grade and inhalation-grade sales have greater ability to pass through labor, energy, freight, and compliance costs. Suppliers concentrated in standard lactose face lower margins and stronger substitution pressure.

Which companies supply pharmaceutical anhydrous lactose?

The principal supplier landscape includes specialized excipient manufacturers and dairy-derived ingredient companies.

Company	Relevant commercial position
DFE Pharma	Global pharmaceutical excipient supplier with multiple lactose grades, direct-compression products, and inhalation-related offerings
MEGGLE	Major lactose producer with pharmaceutical-grade and inhalation-related lactose products
Kerry	Global excipient and pharmaceutical ingredient supplier with lactose and formulation-support capabilities
Roquette	Broad excipient portfolio; competitive in pharmaceutical fillers and tableting systems
Regional dairy-derived excipient manufacturers	Often compete on geographic proximity, cost, and selected pharmacopeial grades

Product names and available grades change by market. Commercial evaluation should distinguish anhydrous lactose from lactose monohydrate, spray-dried lactose, agglomerated lactose, and inhalation carrier grades.

What regulatory standards apply to anhydrous lactose?

Anhydrous lactose is regulated primarily as an excipient rather than as an active pharmaceutical ingredient. Its acceptability depends on compendial compliance, supplier controls, and use in a finished drug product.

United States

Relevant controls include:

• USP-NF monograph requirements for lactose and related material specifications.
• FDA Inactive Ingredient Database listings for approved routes and dosage forms.
• Drug Master File or equivalent confidential quality documentation where used by the supplier.
• Current good manufacturing practice expectations under 21 C.F.R. Parts 210 and 211.
• Nitrosamine, elemental impurity, microbial, and residual contaminant assessments where applicable.

The FDA Inactive Ingredient Database is useful for assessing prior use, but an entry does not automatically establish suitability for every route, dose, or formulation.

European Union

Relevant controls include:

• European Pharmacopoeia monographs.
• EU GMP expectations for excipient risk management.
• Supplier qualification and audit requirements.
• Regulation of excipient manufacturing and distribution through quality agreements and documented supply chains.

The European Commission’s excipient guidance places responsibility on the finished-product manufacturer to assess the appropriate level of excipient manufacturer controls based on risk.

Japan and other markets

Japan, China, India, and other regulated markets generally rely on applicable local pharmacopoeial standards, approved supplier documentation, and finished-product registration requirements. Multinational suppliers benefit from harmonized dossiers and established global quality systems.

What formulation patents protect products containing anhydrous lactose?

Anhydrous lactose itself has limited practical patent protection because lactose is an established chemical excipient. The relevant IP usually protects a formulation, dosage form, process, or particle-engineering method that happens to include anhydrous lactose.

Potential patent categories include:

1. Direct-compression formulations. Claims may cover ratios of active ingredient, anhydrous lactose, binder, disintegrant, and lubricant.
2. Moisture-sensitive formulations. Claims may define low-water compositions for APIs vulnerable to hydrolysis.
3. Orally disintegrating tablets. Claims may cover particle size, porosity, compression force, and disintegration time.
4. Dry-powder inhalers. Claims may cover carrier morphology, fine-particle fractions, lactose surface treatment, and drug-carrier adhesion.
5. Manufacturing methods. Claims may address drying, milling, crystallization, agglomeration, or particle classification.
6. Combination products. Claims may cover a drug device, inhalation cartridge, capsule, or delivery system containing lactose.

Patent risk must therefore be assessed at the finished-product level. A supplier’s sale of anhydrous lactose does not, by itself, create freedom to operate for a formulation using the material.

When does anhydrous lactose lose exclusivity?

Anhydrous lactose has no single product-wide exclusivity date. It is a long-established excipient with multiple suppliers and public compendial specifications.

The relevant exclusivity events are:

Exclusivity issue	Assessment
Compound exclusivity	Not applicable in the conventional pharmaceutical sense
Orange Book exclusivity	Applies to approved drug products, not the excipient as a standalone substance
Supplier patent term	Depends on specific particle-engineering or manufacturing claims
Formulation patent term	Depends on the drug product and jurisdiction
Regulatory exclusivity	Generally attaches to the finished drug or biologic, not lactose
Trade-secret protection	Can cover manufacturing parameters and grade consistency

What is the Orange Book status of anhydrous lactose?

Anhydrous lactose is not an Orange Book-listed drug product. The FDA Orange Book identifies approved drug products, patents, and exclusivity associated with those products. It does not create an Orange Book exclusivity estate for an excipient supplier.

Anhydrous lactose may appear in approved products as an inactive ingredient. Finished-product sponsors may list patents covering formulations or methods of use that include lactose, but those patents belong to the drug product’s regulatory and patent strategy.

Are Paragraph IV challenges relevant to anhydrous lactose?

Paragraph IV litigation is generally not directed at anhydrous lactose as an excipient. It arises when a generic applicant certifies that a listed drug patent is invalid, unenforceable, or will not be infringed.

Anhydrous lactose becomes relevant indirectly when:

• A generic uses the same or an equivalent excipient composition.
• The branded product claims a specific lactose grade or particle profile.
• The branded product claims a moisture-controlled formulation.
• A method-of-use patent depends on a particular dosage-form performance.
• The generic applicant must design around a formulation patent.

Most generic entry risk is therefore tied to the branded drug’s formulation and method-of-use patents, not to a standalone lactose patent.

What manufacturing and intellectual-property barriers affect suppliers?

The strongest barriers are operational and regulatory rather than classic composition-of-matter patents.

Manufacturing barriers

• Consistent low moisture content.
• Controlled particle-size distribution.
• Reproducible bulk density and flow.
• Low microbial burden.
• Control of dairy-derived contaminants.
• Compliance with pharmacopeial testing.
• Scale-up without changing compaction performance.
• Validated cleaning and cross-contamination controls.
• Reliable global logistics.

Intellectual-property barriers

• Proprietary drying and crystallization conditions.
• Particle-engineering processes.
• Surface modification and carrier treatment.
• Formulation-specific performance data.
• Customer-specific specifications.
• Trade secrets covering process controls and analytical methods.

Supplier switching can require new tabletability studies, blend uniformity testing, dissolution work, stability studies, and regulatory change assessments. These costs support customer retention even where formal patent protection is limited.

How does anhydrous lactose compare with competing pharmaceutical excipients?

Excipient	Main advantage	Main limitation
Microcrystalline cellulose	Strong compaction and broad formulation utility	Can affect disintegration, flow, and moisture behavior
Mannitol	Good mouthfeel and low hygroscopicity	Higher cost and different compression profile
Dicalcium phosphate	Low moisture sensitivity and strong density	Brittle behavior and formulation limitations
Starch derivatives	Low cost and disintegration utility	Variable compaction and moisture performance
Anhydrous lactose	Established safety, direct-compression utility, and broad customer familiarity	Dairy origin, supplier qualification, and grade-specific performance

Anhydrous lactose is most competitive where formulators need a familiar, pharmacopeial filler with low moisture and acceptable compaction. It is less differentiated in conventional wet-granulated tablets where standard lactose monohydrate or starch-based fillers may meet the specification.

What generic launch risks exist for products using anhydrous lactose?

Generic launch risk depends on the finished drug’s patent estate, not the presence of lactose alone.

Low-risk scenario

A generic uses a standard pharmacopeial anhydrous lactose grade in a conventional tablet, and the branded product has no enforceable formulation claims directed to lactose or excipient ratios.

Moderate-risk scenario

The branded product claims a narrow composition, tablet hardness, dissolution profile, moisture level, or particle-size range that could read on the generic formulation.

High-risk scenario

The branded product combines anhydrous lactose with a device, inhalation carrier system, controlled-release matrix, or manufacturing process protected by multiple patents.

The practical generic strategy is often to use a different lactose grade, replace lactose with microcrystalline cellulose or mannitol, or alter the manufacturing process to avoid claim elements. Bioequivalence, stability, and manufacturability determine whether a design-around is commercially viable.

Which licensing deals affect anhydrous lactose?

Public licensing activity is limited at the excipient-molecule level. Commercial arrangements more often involve:

• Long-term supply contracts.
• Preferred-supplier agreements.
• Regional distribution rights.
• Contract manufacturing and toll processing.
• Technology transfer for particle engineering.
• Co-development of inhalation carriers.
• Formulation development agreements with drug sponsors.

These arrangements may not be publicly disclosed unless they involve a listed company, a material acquisition, or a drug-device partnership. The commercial value generally lies in supply continuity, grade qualification, and technical support rather than a royalty-bearing lactose license.

What is the competitive outlook for pharmaceutical anhydrous lactose?

The outlook is stable to moderately positive.

Factor	Expected effect
Generic tablet production	Supports volume
Direct compression adoption	Supports premium grades
Moisture-sensitive APIs	Supports anhydrous specifications
Inhalation growth	Supports engineered carrier grades, not automatically anhydrous lactose
Dairy and energy inflation	Pressures margins
Supplier consolidation	Supports pricing but raises concentration risk
Excipient substitution	Caps long-term pricing power
Regulatory scrutiny	Favors established suppliers
Customer dual sourcing	Limits dependence on any single producer

The strongest financial opportunity is in differentiated pharmaceutical grades, not bulk lactose. Suppliers with validated direct-compression and inhalation platforms should capture better margins than producers selling undifferentiated material.

What financial metrics matter for anhydrous lactose suppliers?

Investors and procurement teams should monitor:

• Pharmaceutical-grade revenue as a percentage of total lactose sales.
• Volume growth by grade.
• Average selling price per kilogram.
• Gross margin after drying and energy costs.
• Capacity utilization.
• Customer concentration.
• Dual-source qualification rates.
• Regulatory observations and product recalls.
• Change-control frequency.
• Lead times and inventory levels.
• Exposure to dairy and whey pricing.
• Share of sales from direct-compression and inhalation grades.

A supplier reporting strong revenue growth but declining pharmaceutical-grade mix may be gaining commodity volume rather than improving strategic position. Margin expansion is more credible when tied to premium-grade adoption, validated capacity, and long-term customer contracts.

Key Takeaways

• Anhydrous lactose is a mature but commercially durable pharmaceutical excipient.
• Its primary uses are direct-compression tablets, capsules, orally disintegrating tablets, and selected inhalation formulations.
• Market growth is expected to be moderate in volume and stronger in value for engineered grades.
• DFE Pharma and MEGGLE are major competitive reference suppliers, with Kerry, Roquette, and regional producers also relevant.
• No standalone Orange Book or Paragraph IV exclusivity applies to anhydrous lactose.
• Patent exposure usually arises from drug formulations, inhalation carriers, dosage forms, and manufacturing processes.
• The strongest barriers are qualification, consistency, low-moisture processing, particle engineering, and regulatory documentation.
• Financial performance depends on premium-grade mix, energy and dairy costs, capacity utilization, and supply reliability.
• Generic launch risk must be assessed against the finished drug’s formulation and method-of-use patents.
• The most defensible commercial position is a qualified, high-functionality grade supported by technical data and dual-region manufacturing capacity.

FAQs

Is anhydrous lactose safe for use in tablets?

Anhydrous lactose is widely used as a pharmaceutical filler and diluent when it complies with applicable pharmacopeial and manufacturing requirements. Product suitability depends on the finished formulation, impurity profile, moisture specification, and patient population.

Is anhydrous lactose suitable for lactose-intolerant patients?

The amount of lactose in a tablet is usually much lower than dietary lactose exposure, but suitability depends on dose, patient sensitivity, and labeling requirements. Lactose intolerance and milk-protein allergy are distinct issues.

Can anhydrous lactose replace microcrystalline cellulose?

It can replace microcrystalline cellulose in some formulations, but direct substitution requires development testing. Compaction, flow, lubricant sensitivity, disintegration, and dissolution may change.

Does anhydrous lactose contain residual water?

Yes. "Anhydrous" means the material does not contain stoichiometric crystallization water in the same manner as lactose monohydrate. It does not mean that the material contains zero measurable moisture.

Is anhydrous lactose used in inhalers?

It can be used in selected inhalation products, but inhalation applications more commonly rely on specifically engineered lactose carrier grades. Particle-size distribution, surface properties, microbial quality, and inhalation performance must be evaluated for each product.

References

1. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.

2. European Commission. (2015). Guidelines of 19 March 2015 on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use. Official Journal of the European Union.

3. Food and Drug Administration. (2024). Inactive Ingredient Database. U.S. Department of Health and Human Services.

4. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Rockville, MD.

6. DFE Pharma. (2024). Pharmaceutical lactose excipients and product information. DFE Pharma.

7. MEGGLE Group GmbH. (2024). Pharmaceutical lactose products and excipient information. MEGGLE.